Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0
|
作者：
Mattos, Bruna RaphaeliSilva [1 ]
Cesca, Marcelle Goldner [1 ]
Leite, Luciana de Moura [1 ]
Tavares, Monique Celeste [1 ]
Silva, Sinara Figueiredo [1 ]
Pirolli, Rafaela [1 ]
Fogassa, Camilla AlbinaZanco [1 ]
Silva, Erick Figueiredo [1 ]
Rocha, Francisca Giselle [1 ]
Loose, Simone Klug [1 ]
Campos, Fernando AugustoBatista [1 ]
Sanches, Solange Moraes [1 ]
de Lima, Vladmir ClaudioCordeiro [1 ]
Ponde, Noam Falbel [1 ]
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS4-40
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
    Ilie, S. M.
    Desmoulins, I.
    Hennequin, A.
    Coureche-Guillaume, K.
    Arnould, L.
    Nathalie, B.
    Bertaut, A.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Shi, Yue
    Lu, Heng
    Zhang, Yiqi
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (02) : 387 - 395
  • [43] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [44] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Yihong Wang
    Kamaljeet Singh
    Don Dizon
    Teresa Graves
    Ali Amin
    Evgeny Yakirevich
    Breast Cancer Research and Treatment, 2021, 186 : 667 - 676
  • [46] Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer?
    Silvia Antolín
    Lucía García-Caballero
    Cristina Reboredo
    Aurea Molina
    Joaquín Mosquera
    Ángel Vázquez-Boquete
    Rosalía Gallego
    Mari Paz Santiago
    Ángel Concha
    Eva Pérez
    Lourdes Calvo
    Tomás García-Caballero
    Virchows Archiv, 2021, 479 : 859 - 859
  • [47] Prognostic factors in nonmetastatic HER2 'low' & HER2 'negative' breast cancer: Single institute experience
    Turkel, A.
    Dogan, M.
    Sertesen, E.
    Karacin, C.
    Irkkan, S. C.
    Ates, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S299 - S300
  • [48] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [49] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [50] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
12345